As long as the outcome is positive, its all good no matter who they please
Phase 3 pivotal trial met its primary endpoint (p = 0.001), demonstrating statistical significance that the product provided pain relief following surgery in the treatment group using ELI-200 compared to the placebo group. Secondary endpoint results were consistent with primary findings and included safety measures.
This positive PHASE 3 trial was a milestone for the company.
From now on its just formality/paperwork wich will take lots of time due to bureaucracy, they can slow us down, BUT THEY CAN NOT STOP US !!!!!!